Table 2.
Multivariable Assessments for progression free survival (PFS) and overall survival (OS).
| Double or Triple Hit / Double Expressor status¥ | ||
|---|---|---|
| PFS | ||
| Parameter | Hazard Ratio (95% CI) | p-value |
| Negative | ref | |
| Positive | 5.8 (1.2–23.3) | 0.03 |
| Response prior to ASCT | 0.03 | |
| CR | Ref | |
| PR | 3.9 (1.2–13.3) | |
| SD | 18.0 (1.3–178.3) | |
| Number of treatment lines prior to ASCT | 0.8 (0.4–1.6) | 0.62 |
| sIPI | ||
| 0/1 | Ref | |
| 2/3 | 0.7 (0.2–2.6) | 0.63 |
| Conditioning Regimen | ||
| BEAM +/− rituximab | Ref | |
| GemBuMel-based | 0.5 (0.1–1.9) | 0.31 |
| OS | ||
| Response prior to ASCT | <0.0001 | |
| CR | ref | |
| PR | 4.2 (2.2–8.7) | |
| SD | 6.5 (1.9–18.5) | |
| PD | 4.7 (0.9–17.2) | |
| Lines of treatment prior to ASCT | 1.1 (0.8–1.5) | 0.45 |
| Conditioning Regimen | ||
| BEAM +/− rituximab | ref | |
| GemBuMel-based | 1.0 (0.5–1.8) | 0.93 |
Abbreviations: DH/DE= double hit/double expressor; ASCT = autologous hematopoietic stem cell transplantation; CR = complete remission; PR = partial remission; SD = stable disease; PD = progressive disease; sIPI = secondary internation prognostic index; BEAM = BCNU, etoposide, cytarabine and melphalan; GemBuMel = gemcitabine, busulfan and melphalan.
¥
Considered positive if either of the following positive: double hit / triple hit / double expressor.Calculated for patients with DLBCL histology only.